- Conditions
- Previously Treated Metastatic Adenocarcinoma of the Pancreas
- Interventions
- CRS-207, nivolumab, GVAX, CY
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- San Francisco, California • Stanford, California • Baltimore, Maryland + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- CRS-207, Pembrolizumab
- Biological
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Pancreatic Cancer
- Interventions
- Tadalafil, Pembrolizumab, Ipilimumab, CRS-207
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
- Interventions
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- GVAX Pancreas, CRS-207, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Biological
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 5
- States / cities
- San Francisco, California • Tampa, Florida • Chicago, Illinois + 2 more
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Interventions
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Biological
- Lead sponsor
- Anza Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Epacadostat, Pembrolizumab, CRS-207, Cyclophosphamide, GVAX Pancreas Vaccine
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer
- Interventions
- CRS-207, Epacadostat, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Gainesville, Florida + 6 more
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Interventions
- CRS-207, Pembrolizumab
- Biological
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, Nivolumab, Ipilimumab, GVAX Pancreas Vaccine, CRS-207
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland